NCIt definition : A humanized, nonfucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed
against the inhibitory receptor sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8)
expressed on human mast cells and eosinophils, with potential anti-inflammatory activity.
Upon administration, lirentelimab targets and binds to Siglec-8 expressed on the surface
of mast cells and eosinophils. This may inhibit mast cell activation and deplete eosinophils
through antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis. This may
reduce abnormal proliferation of mast cells and eosinophils, which plays a key role
in allergic and inflammatory responses.;
UNII : SWS48LJU3T;
CAS number : 2283348-97-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2283348-97-8
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;